Next Issue
Volume 2, June
Previous Issue
Volume 1, December
 
 

Dermato, Volume 2, Issue 1 (March 2022) – 2 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
6 pages, 651 KiB  
Case Report
Hyperpigmented Scleroderma-like Lesions under Combined Pembrolizumab and Pemetrexed Treatment of Non-Small Lung Cancer
by Thilo Gambichler, Yi-Pei Lee, Milan Barras, Christina H. Scheel and Laura Susok
Dermato 2022, 2(1), 8-13; https://0-doi-org.brum.beds.ac.uk/10.3390/dermato2010002 - 17 Mar 2022
Cited by 2 | Viewed by 3896
Abstract
Immune checkpoint inhibitors (ICI) and other antineoplastic treatment regimens can trigger cutaneous immune-related adverse events (irAEs). There is a tendency for underreporting of such cases, as cutaneous irAEs are typically perceived as mild and transient. However, more serious cutaneous irAEs can occur which, [...] Read more.
Immune checkpoint inhibitors (ICI) and other antineoplastic treatment regimens can trigger cutaneous immune-related adverse events (irAEs). There is a tendency for underreporting of such cases, as cutaneous irAEs are typically perceived as mild and transient. However, more serious cutaneous irAEs can occur which, despite their lower frequency, deserve attention and require specific care. Here, we report a case of extensive hyperpigmented scleroderma-like lesions (SLL) on the lower extremities under combination treatment with pembrolizumab and pemetrexed in a patient with metastatic non-small cell lung cancer. The present case in conjunction with a review of the current literature underscores the potential risk of developing SLL under treatment with anti-PD-1 antibody and/or pemetrexed. Moreover, it is possible that this particular combination treatment synergistically increases the risk of SLL. As a result, more such cases may arise in the future, as ICI/pemetrexed combination treatment might be employed more often. As drug-induced SLL usually require systemic treatment with high dose-corticosteroids, physicians should be aware of SLL as an irAE when cancer patients present with sclerotic and/or fibrotic skin lesions. Full article
Show Figures

Figure 1

7 pages, 906 KiB  
Review
Augmented and Virtual Reality in Dermatology—Where Do We Stand and What Comes Next?
by Mathias Bonmarin, Severin Läuchli and Alexander Navarini
Dermato 2022, 2(1), 1-7; https://0-doi-org.brum.beds.ac.uk/10.3390/dermato2010001 - 25 Jan 2022
Cited by 4 | Viewed by 5076
Abstract
As the skin is an accessible organ and many dermatological diagnostics still rely on the visual examination and palpation of the lesions, dermatology could be dramatically impacted by augmented and virtual reality technologies. If the emergence of such tools raised enormous interest in [...] Read more.
As the skin is an accessible organ and many dermatological diagnostics still rely on the visual examination and palpation of the lesions, dermatology could be dramatically impacted by augmented and virtual reality technologies. If the emergence of such tools raised enormous interest in the dermatological community, we must admit that augmented and virtual reality have not experienced the same breakthrough in dermatology as they have in surgery. In this article, we investigate the status of such technologies in dermatology and review their current use in education, diagnostics, and dermatologic surgery; additionally, we try to predict how it might evolve in the near future. Full article
(This article belongs to the Collection Artificial Intelligence in Dermatology)
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop